Entrepreneurship in Life Sciences Rijeka, 25-26 April 2013

25th April 2013 Rijeka Croatia



Project funded by the EU



Translational Medicine, Technology Transfer and IPR: Lessons from Europe (and beyond...)

Dr Lisa Cowey MBA PG Cert IP T3I Ltd Oxford UK





Project funded by the EU





Over-view

- Translational medicine: 'bench to bedside' research
- Drivers of new models
- The emerging role of pre-competitive research and the PPP
- Examples of PPP inititives in Europe and other countries
- The impact on IPR management
- The implications for TTOs and metrics



TransModRI



- An effort to carry scientific knowledge from 'bench to bedside'
- research where laboratory findings lead to the development of therapeutics for treating and preventing disease.
- Does this fit to a traditional model of Innovation?






Trans Mod RI




Does translational medicine follow a pipeline model?

The pipeline model of innovation assumes that reliance on high IPR enforcement and limited sharing are the best ways to facilitate further pharmaceutical innovation

TRUE????




A ROADMAP FROM BENCH TO CLINIC





Key bottlenecks in pharmaceutical and development process





Center for Advanced Translational Science (USA) NCATS

strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients.



Trans Med RI

National Center for Advancing Translational Sciences

Policy issues

- Models for Precompetitive Collaboration
- Translational Research Policy
- Intellectual Property for Collaborative Projects

http://www.ncats.nih.gov





Driving new models of innovation for drug discovery

Drivers

- High costs
- Duplication of effort
- Diminishing levels of product development

Collaborators

- Academia
- Industry
- Government
- Nongovernment organizations
- Patient organizations

Trans Med RI

No single pharmaceutical company has the necessary breadth and depth of expertise and resource








Project Funded by the EU

Pre-competitive research collaborations

EMBOreports VOL10 | NO9 | 2009



Closed collaboration between a company and an academic researcher. IPR owned typically by company.

Several parties contribute to a joint project. Results and/or intellectual property rights are normally retained by consortium members.

A joint project, governed by its funders, is carried out at a host institution or as a separate legal entity. Results are made freely *available to allow research in the public domain.*

Trans Med RI



Pre-competitive research collaborations

PUBLIC-PRIVATE PARTNERSHIP	PUBLIC DOMAIN	COMMERCIAL
Tools and basic knowledge Development of chemical probes • Screening • Medicinal chemistry • Structural biology • Bioavailability	Discovery and exploration Open access to tools and data Target identification and validation	Drug discovery and development Facilitated by access to increased amounts of information in the public domain
Output open to all		
CREATIVE	COMMONS	PROPRIETARY

Results—tools and data—are shared freely to facilitate further exploration and new discoveries. Increased knowledge will allow commercial projects at a later stage with an increased chance of success.



Project Funded by the EU

EMBOreports VOL10 | NO9 | 2009

T₃I



Structural Genomics Consortium



- not-for-profit, public-private partnership
- engaged in pre-competitive research to facilitate the discovery of new medicines
- generating reagents and knowledge related to human proteins and proteins from human parasites
- Operates an Open Access Model

"The SGC and its scientists are committed to making their research outputs (materials and knowledge) available without restriction on use. This means that the SGC will promptly place its results in the public domain and will not agree to file for patent protection on any of its research outputs. It will seek the same commitment from any research collaborator."



Community resources: Jackson Laboratory JAX



Leading the search for tomorrow's cures

JAX® Mice & Services 2013-14 Catalog Order today

TransModRI

JAX ensures that donors accept a **research commons approach** for academics in return for JAX acting as a bridge between donors and industry

Τ3Ι

www.jax.org



Project Funded by the EU




🕶 🗢 TIPharma

- TI Pharma is an non-profit organization
- provides governance for complex often pre-competitive- partnership projects.
 Independent research enabler:
 - transparency and reliability to collaborating partners
 - ➢ fosters the realization of joint research goals.
 - "Custodian of trust"



Trans Mod RI



- "research projects are... focused on research that is difficult or impossible for individual companies to perform"
- PPP types:
 - (1) product development partnerships to develop products in areas of market failure, and
 - > (2) knowledge development.




• <u>http://www.tipharma.com</u>



TransMedR



TMRC Translational Medicine Research Collaboration





Launched 2006 **T³I**

Trans Med RI



TMRI

- Principal delivery and exploitation vehicle for the Scottish Translational Medicine Research Collaboration
- Shared Goals, Shared Risks and ultimately Shared Rewards











Innovative Medicines Initiative

- Europe's largest public-private initiative.
- Aiming to speed up the development of better and safer medicines for patients.
- Supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
- A joint undertaking between the European Union and the pharmaceutical industry association EFPIA.










- IMI The IMI Intellectual Property (IP) Policy governs the IP regime of all projects funded by the IMI
- To promote knowledge creation, together with its disclosure and exploitation
- To achieve fair allocation of rights
- To reward innovation
- To provide some scope of flexibility for participants to establish the most appropriate agreements serving the project objectives (-> Project Agreement, i.e. agreement between the participants)



Trans Med RI

One policy, multiple interests









- It was once said that everything in life is a PPP 'otherwise it is just an idea gathering dust on a shelf' Ruxandra Draghia-Akli
- There is a lot of value that PPPs can add; however good governance and the promotion of excellence is essential Willem De Laat
- The early achievements confirm that IMI is on track to achieve its goals Michel Goldman
- It is clear from what we have heard today that partnerships across regions and public-private initiatives are the way forward Lambert Van Nistelrooij



TransMedR

Enhancing Translational Research Collaborations -Rethinking IPR strategy?





Project Funded by the EU

Τ³Ι

Trans Med RI

	,						
Knowledge system	Public domain	Common pool resources	Open source	Open access	Open innovation s	trategies	Closed innovation
Goal	Access to knowledge; minimal transaction costs	Creation of re- sources of research tools and databases within a managed environment	Construction of a web of users who share knowledge and materials through legal agreements	Creation of norms to facilitate access to knowledge and collaboration	Facilitation of knowledge ex- change about IPRs or trade in patents and other IPRs	Facilitation of Joint Research Partnerships	Maximal control over all stages of re- search through product devel- opment and marketing
IP strategy/ mechanism	IPRs expired or ineligible. Specific pub- lic domain dedication	Licenses/simple agreements bal- ance access with other considerations such as resource sustainability (such as cost recovery), sensitivity (animal welfare, safety, and confidentiality), and attribution	Viral licensing mainly for copy- righted material. Improvements shared under the same open terms as applied to original	Collaborators and funders create clear rules on how knowledge is produced and used and enforce those rules. Does not necessarily rely on IPRs	Internet communi- cations platforms on licensing and partnerships; auctions; exchang- es; patent pools; clearinghouses	Exchange programs, research alliances, public-private partnerships	Vertically integrated firms reliant on strong IPR protection, including patent, trademark, and data exclusivity
Use	Data/ databases	Research tools/ databases	Software and other copyrighted material	Research tools and data	Patented inven- tions available for licensing	Precompeti- tive research	Research, product devel- opment, and marketing
Examples	GenBank; Mouse Genomics Informatics (MGI)	JAX Mice; European Mutant Mouse Ar- chive; International HapMap Project; SAGE Data Reposi- tory	Linux; BioBricks; BiOS	Structural Genom- ics Consortium	Flintbox; BIO Ventures for Health; Medicines Patent Pool; MPEG LA clearinghouse for molecular diag- nostics	Innovative Medicines Initiative	Traditional pharmaceutical business model
Pro	Bubela	a et al ScienceTra l EU	nslationalMedici	ine.org 22 Febru T ³ l		ssue 122 ransMed	IRI





Intermediate input-output measures e.g.: \gg # Invention disclosures >Licensing re ➤#Spinout • Encourage a and the treatment of T Developmer Research Diffusion emonstration 1 runs/ ledK T₃I Project Funded by the EU

	Input	Process	Output	Outcome
Networks	Number and diversity of partners	Exchange of information between partners	Number of projects continued after PPP funding	Number and size of new partnerships inspired by PPPs
Know-how	Formal knowledge sharing; for example, background IP in consortia	Knowledge sharing through percentage of personnel exchanged and number of consortia meetings	Number and citation score for joint publications	Number of products in clinical development based (partially) on knowledge genarated in PPPs
Human capital	Number of experts involved, number of highly cited researchers	Percentage of researchers trained via PPP-specific courses	Number of completed PhDs and postdoctoral positions	Percentage of trained researchers working in R&D positions in the sector
Financials and operations	Total research funding available in partnership	Percentage of researchers and staff using intranet on a regular basis	Percentage of milestones achieved in consortia	Return on investment after 5 years at industrial partners and in start-ups

Nature Reviews Drug Discovery | AOP, published online 30 March 2012



Conclusions

- Translational medicine requires new models of innovation and IPR management for optimum operation
- Pre-competitive research collaborations require clear negotiations around IPRs as both inputs and outputs of the collaboration
- Harnessing the 'potential' of Public Private Partnerships (PPPs) can help put Europe at the forefront of pharmaceutical research and development.
- Focus on IPR Management and not IPR regimes
- Rethink associated metrics to measure impact



TransMedR



Comments and Questions?

Lisa Cowey PhDMBA PG Cert IP <u>I.cowey@t3i.co.uk</u>





